Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
AssigneeTheravance Biopharma R&D IP, LLC
InventorPaul R. Fatheree
Life of this patent
Estimating the term…
Abstract
The invention provides crystalline salt forms of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]-imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid. This invention also provides pharmaceutical compositions comprising the crystalline compounds, processes and intermediates for preparing the crystalline compounds, and methods of using the crystalline compounds to treat diseases such as hypertension.
Claims7
A solid pharmaceutical composition comprising a blended mixture of a pharmaceutically acceptable carrier and crystalline hemiedisylate salt form II of 4′-{2-ethoxy-4-ethyl-5-[((S)-2-mercapto-4-methylpentanoylamino)methyl]imidazol-1-ylmethyl}-3′-fluorobiphenyl-2-carboxylic acid, characterized by a powder x-ray diffraction pattern comprising diffraction peaks at 2θ values of 9.74±0.20, 11.00±0.20, 12.89±0.20, 14.27±0.20, 15.54±0.20, 18.62±0.20, and 23.78±0.20;
- wherein said composition is shaped or loaded into tablets or capsules.
Dependencies are inferred from the claim text.